At a glance
- Originator Fujisawa
- Class Antibacterials; Small molecules
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Helicobacter infections
Most Recent Events
- 24 Aug 2001 No-Development-Reported for Helicobacter infections in Japan (Unknown route)
- 30 Nov 1998 New profile
- 30 Nov 1998 Preclinical development for Helicobacter infections in Japan (Unknown route)